EXPERT OPINION ON INVESTIGATIONAL DRUGS
metrics 2024
Driving Progress in Investigational Medicine
Introduction
Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.
Metrics 2024
Metrics History
Rank 2024
Scopus
IF (Web Of Science)
JCI (Web Of Science)
Quartile History
Similar Journals
Clinical Pharmacology-Advances and Applications
Exploring New Frontiers in Pharmacological ScienceClinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.
Pharmacy & Pharmacology-Farmatsiya i Farmakologiya
Exploring the nexus of pharmacy and pharmacology.Pharmacy & Pharmacology-Farmatsiya i Farmakologiya is a distinguished journal published by the Pyatigorskii Mediko-Farmatsevticheskii Inst in the Russian Federation, dedicated to advancing research in the fields of pharmacy and pharmacology. Since its transition to an Open Access format in 2013, it has become an invaluable resource for researchers and professionals seeking to disseminate and access high-quality findings. With its ISSN 2307-9266 and E-ISSN 2413-2241, this journal covers a broad range of topics, providing a platform for the latest developments in pharmaceutical sciences. It is noteworthy that, as of 2023, Farmatsiya i Farmakologiya is categorized in various quartiles, with its Q2 ranking in Pharmacology (nursing) and Q3 in Pharmacy indicating its growing impact and relevance within its field. With the journal's commitment to fostering innovation and collaboration in pharmacy and pharmacology research, it serves as an essential hub for academics, practitioners, and students aiming to contribute to and stay informed about the dynamic landscape of this critical discipline.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
Enhancing medical practice through cutting-edge research findings.CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.
EXPERT OPINION ON EMERGING DRUGS
Exploring the future of pharmacology, one drug at a time.EXPERT OPINION ON EMERGING DRUGS, published by Taylor & Francis Ltd, stands at the forefront of the pharmacological sciences, focusing on the rapid development and evaluation of innovative therapeutic agents. With an impressive impact factor that reflects its contributions to the field, this journal is indexed under ISSN 1472-8214 and E-ISSN 1744-7623. The journal has consistently attained high recognition, currently holding a Q2 ranking in Pharmacology and a Q1 ranking in Pharmacology (medical) as of 2023, which places it within the top tiers of scholarly publications. Covering a broad range of topics related to emerging pharmaceuticals, it aims to bridge the gap between research and clinical practice by providing critical reviews, expert opinions, and insightful analyses. Based in the United Kingdom and actively published since 2000, the journal seeks to inform and inspire researchers, professionals, and students alike, offering a platform to foster collaboration and insight within the ever-evolving domain of drug development and pharmacotherapy.
CNS DRUGS
Leading the Charge in Neuroscience InnovationCNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.
CLINICAL PHARMACOLOGY & THERAPEUTICS
Advancing pharmacological knowledge for better patient care.CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.
CURRENT PHARMACEUTICAL DESIGN
Pioneering Insights in Pharmacology and Drug DevelopmentCURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Enhancing Understanding of Pharmacological Treatments and ToxicologyBASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.
Drug Research
Exploring New Horizons in Drug DiscoveryDrug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.
MOLECULAR PHARMACOLOGY
Advancing the Science of Drug ActionMOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.